Abstract
In this paper we analyze the strategic response of Japanese pharmaceutical firms to increased competitive pressure. During the 1980’s and 1990’s entry barriers were lifted and markets deregulated. As a consequence transaction structures moved from a relationship based mode towards a market based mode where competition is based on research excellence and new and innovative products. Using panel data of a sample of Japanese pharmaceutical companies, this paper discusses the effect of international patents as an indicator of research capabilities on subsequent corporate performance measured as profits on total assets. Our empirical result suggests that a firm’s patent stock is unrelated or even negatively correlated to its profitability.
Similar content being viewed by others
Notes
Other sources estimates are even higher. Bain & Co. estimates that the average cost per successful drug launch is $1.7 billion. And a 2003 report by the US Department of Commerce found that every $1.3 billion invested in R&D should, on average, yield one new medicine in the marketplace.
References
Cockburn, I., & Griliches, Z. 1988. Industry effects and appropriability measures in the stock market’s valuation of R&D and patents. American Economic Review, 78: 419–423.
Comanor, W. S., & Scherer, F. M. 1969. Patent statistics as a measure of technical change. Journal of Political Economy, 77: 392–398.
Czarnitzki, D., & Kraft, K. 2008. On the profitability of innovative assets. Applied Economics, forthcoming.
D’Aunno, T., Succi, M., & Alexander, F. 2000. The role of institutional and market forces in divergent organizational change. Administrative Science Quarterly, 45: 679–703.
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. 2003. The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22: 151–185.
Ernst, H. 2001. Patent applications and subsequent changes of performance: Evidence from time series cross section analyses on the firm level. Research Policy, 30: 143–157.
Fleischer, M. 1999. Innovation, patenting, and performance. Economie Appliquée, 52: 95–119.
Grabowski, H., Vernon, J., & DiMasi, J. 2003. Returns on research and development for 1990’s new drug introductions. PharmacoEconomics, 20: 11–29.
Griliches, Z. 1981. Market value, R&D, and patents. Economic Letters, 7: 183–187.
Griliches, Z., Hall, B., & Pakes, A. 1991. R&D, patent, and market value revisited: Is there a second (technological opportunity) factor. Economics of Innovation and New Technology, 1: 183–201.
Gschwandtner, A., & Cable, J. 2008. On modeling the persistence of profits in the long run: An analysis of 156 US companies, 1950–1999. International Journal of the Economics of Business, 15: 245–263.
Haneda, S., & Odagiri, H. 1998. Appropriation from returns from technological assets and the values of patents and R&D in the Japanese high-tech firms. Economics of Innovation and New Technologies, 7: 303–321.
Hausman, J. A. 1978. Specification tests in econometrics. Econometrica, 46: 1251–1271.
Hiraki, T., Inoue, H., Ito, A., Kuroki, F., & Masuda, H. 2003. Corporate governance and firm value in Japan: Evidence from 1985–1998. Pacific Basin Finance Journal, 11: 239–265.
Huttin, C. 1995. The Japanese drug price policy: A new dynamic on price competition. Journal of Research in Pharmaceutical Economics, 4: 21–34.
IMS Health. 2006. IMS world review. Fairfield: Intercontinental Medical Statistics.
JPA. 2004. Annual report. Tokyo: Japan Pharmaceutical Association.
Kawaura, A., & La Croix, S. J. 1995. Japan’s shift from process to product patents in the pharmaceutical industry: An event study of the impact on Japanese firms. Economic Inquiry, 33: 88–103.
Levin, R. C., Klevorick, A. K., Nelson, R. R., & Winter, S. G. 1987. Appropriating the returns from industrial research and development. Brooking Papers on Economic Activity, 3: 783–831.
Mahlich, J. 2007. The Japanese pharmaceutical industry in transition: Has higher research orientation resulted in higher market value. Asian Business and Management, 6: 75–94.
Mahlich, J., & Roediger-Schluga, T. 2002. New opportunities for Asian pharmaceutical firms. Asia Pacific Tech Monitor, Jan–Feb: 40–45.
Mahlich, J., & Roediger-Schluga, T. 2006. The determinants of pharmaceutical R&D expenditures: Evidence from Japan. Review of Industrial Organization, 28(2): 145–164.
Mansfield, E. 1986. Patents and innovation, an empirical study. Management Science, 32: 173–181.
Mansfield, E., Schwartz, M., & Wagner, S. 1981. Imitation costs and patents: An empirical study. Economic Journal, 91: 907–918.
Megna, P., & Klock, M. 1993. The impact of intangible capital on Tobin’s q in the semiconductor industry. American Economic Review, 83(2): 265–269.
Moen, Ø. 1999. The relationship between firm size, competitive advantages and export performance revisited. International Small Business Journal, 18: 53–72.
Morck, R., Nakamura, M., & Shivdasani, A. 2000. Banks, ownership structure, and firms value in Japan. Journal of Business, 4: 539–567.
Mueller, D. 1986. Profits in the long run. Cambridge: Cambridge University Press.
Munshi, K., & Reich, M. 1994. Investment behavior and financial structure: The case of the Japanese pharmaceutical industry. Working paper no. 17–94, MIT Sloan School of Management.
Narin, F., Noma, E., & Perry, R. 1987. Patents as indicators of corporate technological strength. Research Policy, 16: 143–155.
Neumann, M., Böbel, I., & Haid, A. 1979. Profitability, risk and market structure in West German industries. Journal of Industrial Economics, 27: 227–242.
Neumann, M., Böbel, I., & Haid, A. 1981. Market structure and the labour market in West German Industries—a contribution towards interpreting the structure performance relationship. Journal of Economics, 41: 97–109.
Nightingale, P. 2000. Economies of scale in experimentation: Knowledge and technology in pharmaceutical R&D. Industrial and Corporate Change, 9: 315–359.
North, D. 1990. Institutions, institutional change, and economic performance. Cambridge: Cambridge University Press.
Oliver, C. 1991. Strategic responses to institutional processes. Academy of Management Review, 16: 145–179.
Pakes, A. 1985. On patents, R&D, and the stock market rate of return. Journal of Political Economy, 93: 390–409.
Pakes, A., & Shankerman, M. 1984. The rate of obsolescence of patents, research gestation lags, and the private rate of return to research resources. In Z. Griliches (Ed.). R&D, patents, and productivity: 455–503. Chicago: University of Chicago Press.
Peng, M. W. 2002. Towards an institution based view of business strategy. Asia Pacific Journal of Management, 19: 251–267.
Peng, M. W. 2003. Institutional transitions and strategic choices. Academy of Management Review, 28: 275–296.
Peng, M. W., Wang, D., & Jiang, Y. 2008. An institution-based view of international business strategy: A focus on emerging markets economies. Journal of International Business Studies, 29: 599–608.
PhRMA. 2003. Industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America.
Rajan, R. G. 1992. Insiders and outsiders: The choice between informed and arm’s-length debt. Journal of Finance, 47: 1367–1400.
Scherer, F. M. 1965. Corporate inventive output, profits and growth. Journal of Political Economy, 73: 290–297.
Shapiro, D. M., & Switzer, L. N. 1993. The stock market response to changing drug patent legislation: The case of compulsory licensing in Canada. Managerial and Decision Economics, May/June: 247–261.
Sharpe, S. A. 1990. Asymmetric information, bank lending and implicit contracts: A stylized model. Journal of Finance, 45: 1069–1087.
Williamson, O. 1985. The economic institutions of capitalism. New York: Free Press.
Yafeh, Y., & Yosha, O. 2003. Large shareholders and banks: Who monitors and how. Economic Journal, 113: 128–146.
Zajac, E., Kraatz, M., & Bresser, R. 2000. Modeling the dynamics of strategic fit. Strategic Management Journal, 21: 429–454.
Author information
Authors and Affiliations
Corresponding author
Additional information
The author wants to thank the editor and the referees for helpful comments.
Rights and permissions
About this article
Cite this article
Mahlich, J.C. Patents and performance in the Japanese pharmaceutical industry: An institution-based view. Asia Pac J Manag 27, 99–113 (2010). https://doi.org/10.1007/s10490-008-9128-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10490-008-9128-x